The most advanced preclinical KDM4 inhibitor is JIB-04 which targets KDM4A, KDM4B, and KDM4E and can inhibit growth and reduce tumor burden in non-small cell lung cancer (NSCLC) and breast cancer in vitro and in vivo (Wang et al., 2013). This evidence concerns the gene KDM4A and breast cancer.